Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating
On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating.

